Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib

Oncotarget

Volumn 8, Issue 36, 2017, Pages 60094-60108

  Noeparast, Amir ^a   Teugels, Erik ^a   Giron, Philippe ^a   Verschelden, Gil ^a   De Brakeleer, Sylvia ^a   Decoster, Lore ^a   De Grève, Jacques ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Dabrafenib; Impaired kinase; Lung cancer; Non V600 BRAF; Trametinib

Indexed keywords

B RAF KINASE; CARBOPLATIN; CASPASE 3; CASPASE 7; CISPLATIN; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; GEMCITABINE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PEMETREXED; SELUMETINIB; TRAMETINIB; VEMURAFENIB;

ADULT; AGE; AGED; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIMERIZATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MISSENSE MUTATION; MONOTHERAPY; NON SMALL CELL LUNG CANCER; NUCLEIC ACID BASE SUBSTITUTION; ONCOGENE H RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PLASMID; PROTEIN FUNCTION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; VERY ELDERLY;

EID: 85029726790     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11635     Document Type: Article

References (64)

1. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014; 14:455-67. https://doi.org/10.1038/nrc3760.
2. Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, Solit DB, Collisson EA, Rudin CM, et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci USA. 2014; 111:E748-57. https://doi.org/10.1073/pnas.1320956111.
3. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, Viola P, Pullara C, Mucilli F, Buttitta F. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011; 29:3574-79. https://doi.org/10.1200/JCO.2011.35.9638.
4. Litvak AM, Paik PK, Woo KM, Sima CS, Hellmann MD, Arcila ME, Ladanyi M, Rudin CM, Kris MG, Riely GJ. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. J Thorac Oncol. 2014; 9:1669-74. https://doi.org/10.1097/JTO.0000000000000344.
5. Kinno T, Tsuta K, Shiraishi K, Mizukami T, Suzuki M, Yoshida A, Suzuki K, Asamura H, Furuta K, Kohno T, Kushima R. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. Ann Oncol. 2014; 25:138-42. https://doi.org/10.1093/annonc/mdt495.
6. Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013; 19:4532-40. https://doi.org/10.1158/1078-0432. CCR-13-0657.
7. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150:1107-20. https://doi.org/10.1016/j.cell.2012.08.029.
8. Niault TS, Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis. 2010; 31:1165-74. https://doi.org/10.1093/carcin/bgp337.
9. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R, and Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004; 116:855-67. https://doi.org/10.1016/S0092-8674(04)00215-6.
10. Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM. Kinaseimpaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med. 2012; 4:136ra70. https://doi.org/10.1126/scitranslmed.3003513.
11. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010; 140:209-21. https://doi.org/10.1016/j. cell.2009.12.040.
12. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006; 439:358-62. https://doi.org/10.1038/nature04304.
13. Kamata T, Hussain J, Giblett S, Hayward R, Marais R, Pritchard C. BRAF inactivation drives aneuploidy by deregulating CRAF. Cancer Res. 2010; 70:8475-86. https://doi.org/10.1158/0008-5472.CAN-10-0603.
14. Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets. 2007; 11:1587-609. https://doi.org/10.1517/14728 222.11.12.1587.
15. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012; 11:909-20. https://doi.org/10.1158/1535-7163.MCT-11-0989.
16. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010; 467:596-99. https://doi.org/10.1038/nature09454.
17. Holderfield M, Nagel TE, Stuart DD. Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. Br J Cancer. 2014; 111:640-45. https://doi.org/10.1038/bjc.2014.139.
18. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010; 464:431-35. https://doi.org/10.1038/nature08833.
19. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010; 464:427-30. https://doi.org/10.1038/nature08902.
20. Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, Tellew J, Hardy S, Hekmat-Nejad M, Stuart DD, McCormick F, Nagel TE. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell. 2013; 23:594-602. https://doi.org/10.1016/j.ccr.2013.03.033.
21. Spagnolo F, Ghiorzo P, Queirolo P. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget. 2014; 5:10206-21. https://doi.org/10.18632/oncotarget.2602.
22. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014; 508:118-22. https://doi.org/10.1038/nature13121.
23. Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013; 19:1401-09. https://doi.org/10.1038/nm.3392.
24. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell. 2012; 22:668-82. https://doi.org/10.1016/j.ccr.2012.10.009.
25. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, et al. EGFRmediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012; 2:227-35. https://doi.org/10.1158/2159-8290.CD-11-0341.
26. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008; 68:4853-61. https://doi.org/10.1158/0008-5472.CAN-07-6787.
27. Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA, Siew K, Lomma C, Cooper A, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015; 6:42008-18. https://doi.org/10.18632/oncotarget.5788.
28. Fedorenko IV, Gibney GT, Sondak VK, Smalley KS. Beyond BRAF: where next for melanoma therapy? Br J Cancer. 2015; 112:217-26. https://doi.org/10.1038/bjc.2014.476.
29. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015; 386:444-51. https://doi.org/10.1016/S0140-6736(15)60898-4.
30. Miller MA, Oudin MJ, Sullivan RJ, Wang SJ, Meyer AS, Im H, Frederick DT, Tadros J, Griffith LG, Lee H, Weissleder R, Flaherty KT, Gertler FB, Lauffenburger DA. Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. Cancer Discov. 2016; 6:382-99. https://doi.org/10.1158/2159-8290.CD-15-0933.
31. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372:30-39. https://doi.org/10.1056/NEJMoa1412690.
32. Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011; 71:7137-40. https://doi.org/10.1158/0008-5472.CAN-11-1243.
33. Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, Ribas A. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015; 7:279ra41. https://doi.org/10.1126/scitranslmed.aaa4691.
34. Planchard D. Interim results of a phase 2 study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA. 2015; Abstract #8006.
35. Atreya CE. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). 2015 ASCO Annual Meeting. 2015; Abstract Number: 103.
36. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. Human malignant melanoma: detection of BRAF-and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol. 2005; 36:486-93. https://doi.org/10.1016/j.humpath.2005.03.015.
37. Agency EM. Tafinlar, summary of product characteristics. European Medicines Agency. 2013.
38. Hu J, Stites EC, Yu H, Germino EA, Meharena HS, Stork PJ, Kornev AP, Taylor SS, Shaw AS. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell. 2013; 154:1036-46. https://doi.org/10.1016/j.cell.2013.07.046.
39. Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, et al. Disruption of CRAFmediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 2014; 25:697-710. https://doi.org/10.1016/j.ccr.2014.03.011.
40. Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015; 16:281-98. https://doi.org/10.1038/nrm3979.
41. Qiu ZX, Wang L, Han J, Liu D, Huang W, Altaf K, Qiu XS, Javed MA, Zheng J, Chen BJ, Li WM. Prognostic impact of Raf-1 and p-Raf-1 expressions for poor survival rate in non-small cell lung cancer. Cancer Sci. 2012; 103:1774-79. https://doi.org/10.1111/j.1349-7006.2012.02375.x.
42. Cekanova M, Majidy M, Masi T, Al-Wadei HA, Schuller HM. Overexpressed Raf-1 and phosphorylated cyclic adenosine 3'-5'-monophosphatate response element-binding protein are early markers for lung adenocarcinoma. Cancer. 2007; 109:1164-73. https://doi.org/10.1002/cncr.22520.
43. Fedorov LM, Papadopoulos T, Tyrsin OY, Twardzik T, Götz R, Rapp UR. Loss of p53 in craf-induced transgenic lung adenoma leads to tumor acceleration and phenotypic switch. Cancer Res. 2003; 63:2268-77.
44. Karreth FA, Frese KK, DeNicola GM, Baccarini M, Tuveson DA. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov. 2011; 1:128-36. https://doi.org/10.1158/2159-8290.CD-10-0044.
45. Blasco RB, Francoz S, Santamaría D, Cañamero M, Dubus P, Charron J, Baccarini M, Barbacid M. c-Raf, but not B-Raf, is essential for development of K-Ras oncogenedriven non-small cell lung carcinoma. Cancer Cell. 2011; 19:652-63. https://doi.org/10.1016/j.ccr.2011.04.002.
46. Freeman AK, Ritt DA, Morrison DK. Effects of Raf dimerization and its inhibition on normal and diseaseassociated Raf signaling. Mol Cell. 2013; 49:751-58. https://doi.org/10.1016/j.molcel.2012.12.018.
47. Zang M, Gong J, Luo L, Zhou J, Xiang X, Huang W, Huang Q, Luo X, Olbrot M, Peng Y, Chen C, Luo Z. Characterization of Ser338 phosphorylation for Raf-1 activation. J Biol Chem. 2008; 283:31429-37. https://doi.org/10.1074/jbc.M802855200.
48. Shin SY, Rath O, Choo SM, Fee F, McFerran B, Kolch W, Cho KH. Positive-and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway. J Cell Sci. 2009; 122:425-35. https://doi.org/10.1242/jcs.036319.
49. Chen J, Fujii K, Zhang L, Roberts T, Fu H. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA. 2001; 98:7783-88. https://doi.org/10.1073/pnas.141224398.
50. Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene. 2011; 30:3477-88. https://doi.org/10.1038/onc.2011.160.
51. Mielgo A, Seguin L, Huang M, Camargo MF, Anand S, Franovic A, Weis SM, Advani SJ, Murphy EA, Cheresh DA. A MEK-independent role for CRAF in mitosis and tumor progression. Nat Med. 2011; 17:1641-45. https://doi.org/10.1038/nm.2464.
52. Wang HG, Reed JC. Bc1-2, Raf-1 and mitochondrial regulation of apoptosis. Biofactors. 1998; 8:13-16. https://doi.org/10.1002/biof.5520080103.
53. Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations Oncogene. 2009; 28:85-94. https://doi.org/10.1038/onc.2008.362.
54. Fofaria NM, Frederick DT, Sullivan RJ, Flaherty KT, Srivastava SK. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Oncotarget. 2015; 6:40535-56. https://doi.org/10.18632/oncotarget.5755.
55. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 2008; 68:9375-83. https://doi.org/10.1158/0008-5472.CAN-08-2223.
56. Joshi M, Rice SJ, Liu X, Miller B, Belani CP. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. PLoS One. 2015; 10:e0118210. https://doi.org/10.1371/journal.pone.0118210.
57. Martin TD, Samuel JC, Routh ED, Der CJ, Yeh JJ. Activation and involvement of Ral GTPases in colorectal cancer. Cancer Res. 2011; 71:206-15. https://doi.org/10.1158/0008-5472.CAN-10-1517.
58. Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, et al. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res. 2013; 19:4149-62. https://doi.org/10.1158/1078-0432. CCR-12-3140.
59. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. 2012; 72:779-89. https://doi.org/10.1158/0008-5472.CAN-11-2941.
60. Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, Kamranpour N, Pitts S, Desai A, Elashoff D, French T, Smith P, Slamon DJ. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther. 2010; 9:1985-94. https://doi.org/10.1158/1535-7163. MCT-10-0037.
61. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 2008; 68:9375-83. https://doi.org/10.1158/0008-5472.CAN-08-2223.
62. Shahi RB, De Brakeleer S, De Grève J, Geers C, In't Veld P, Teugels E. Detection of EGFR-TK domain-activating mutations in NSCLC with generic PCR-based methods. Appl Immunohistochem Mol Morphol. 2015; 23:163-71. https://doi.org/10.1097/PDM.0000000000000035.
63. Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene. 2008; 27:5303-14. https://doi.org/10.1038/onc.2008.164.
64. Newhouse BJ, Wenglowsky S, Grina J, Laird ER, Voegtli WC, Ren L, Ahrendt K, Buckmelter A, Gloor SL, Klopfenstein N, Rudolph J, Wen Z, Li X, Feng B. Imidazo[4,5-b]pyridine inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2013; 23:5896-99. https://doi.org/10.1016/j.bmcl.2013.08.086.